How to improve R&D productivity: the pharmaceutical industry's grand challenge

SM Paul, DS Mytelka, CT Dunwiddie… - Nature reviews Drug …, 2010 - nature.com
The pharmaceutical industry is under growing pressure from a range of environmental
issues, including major losses of revenue owing to patent expirations, increasingly cost …

Chemometrics in metabolomics—a review in human disease diagnosis

R Madsen, T Lundstedt, J Trygg - Analytica chimica acta, 2010 - Elsevier
Metabolomics is a post genomic research field concerned with developing methods for
analysis of low molecular weight compounds in biological systems, such as cells, organs or …

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease

DM Good, P Zürbig, A Argiles, HW Bauer… - Molecular & cellular …, 2010 - ASBMB
Because of its availability, ease of collection, and correlation with physiology and pathology,
urine is an attractive source for clinical proteomics/peptidomics. However, the lack of …

Subgroup identification based on differential effect search—a recursive partitioning method for establishing response to treatment in patient subpopulations

I Lipkovich, A Dmitrienko, J Denne… - Statistics in …, 2011 - Wiley Online Library
We propose a novel recursive partitioning method for identifying subgroups of subjects with
enhanced treatment effects based on a differential effect search algorithm. The idea is to …

Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type

MA Subhan, F Parveen, H Shah, SSK Yalamarty… - Cancers, 2023 - mdpi.com
Simple Summary The progress of next-generation sequencing technologies has raised
huge expectations for precision-medicine therapy approaches in breast cancer and triple …

[HTML][HTML] The faces of personalized medicine: a framework for understanding its meaning and scope

WK Redekop, D Mladsi - Value in Health, 2013 - Elsevier
The objective of this article was to provide a framework for understanding the different
definitions of the term “personalized medicine.” The term personalized medicine is used …

The FDA critical path initiative and its influence on new drug development

J Woodcock, R Woosley - Annu. Rev. Med., 2008 - annualreviews.org
Societal expectations about drug safety and efficacy are rising while productivity in the
pharmaceutical industry is falling. In 2004, the US Food and Drug Administration introduced …

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use

FW Frueh, S Amur, P Mummaneni… - … : The Journal of …, 2008 - Wiley Online Library
Study Objectives. To review the labels of United States Food and Drug Administration (FDA)‐
approved drugs to identify those that contain pharmacogenomic biomarker information, and …

Ethinyl estradiol and other human pharmaceutical estrogens in the aquatic environment: a review of recent risk assessment data

JP Laurenson, RA Bloom, S Page, N Sadrieh - The AAPS journal, 2014 - Springer
Interest in pharmaceuticals in the environment has increased substantially in recent years.
Several studies in particular have assessed human and ecological risks from human …

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum

I Raz, MC Riddle, J Rosenstock, JB Buse, SE Inzucchi… - 2013 - Am Diabetes Assoc
In June 2012, 13 thought leaders convened in a Diabetes Care Editors' Expert Forum to
discuss the concept of personalized medicine in the wake of a recently published American …